Assoc Professor Alex Menzies
Alexander Menzies is a Medical Oncologist and Associate Professor of Melanoma Medical Oncology at Melanoma Institute Australia (MIA), The University of Sydney, and Royal North Shore and Mater Hospitals.
He received his PhD in 2015 for research exploring the biology of BRAF-mutant melanoma and biomarkers of response and resistance to targeted therapy, and has an impressive track record for clinical and translational research for this early stage in his career. Since 2009 he has been an investigator on over 80 sponsored and investigator-led Phase I to III clinical trials of systemic therapies in melanoma, and in the last 5 years has over 85 publications with more than 2000 citations in journals such as Nature, Lancet Oncology, Nature Communications, Journal of Clinical Oncology, Annals of Oncology and Clinical Cancer Research.
Alexander conducts several investigator-led and sponsored clinical trials, manages the medical oncology clinical and biospecimen databases at MIA that underpin clinical and translational research, and serves as a faculty member and research committee member at MIA. He has co-established an international clinical research collaboration network between several major Australian, USA and European melanoma centres providing opportunities for junior research staff leading to high impact original research publications, and is a founding member of the international neoadjuvant melanoma consortium (INMC).
His main research interests are clinical trials of new systemic therapies for melanoma, biomarkers of response and resistance to systemic therapy, and immunotherapy-related toxicity.
Carol Oliver says:
Gunter Mai says:
Kerry Bray says: